Head-to-head · free
Revolution Medicines, Inc. vs Sight Sciences, Inc.
RVMD vs SGHT — return on capital, cash generation, margins and balance sheet side by side.
RVMD
1 / 6
measures where RVMD leads
SGHT
5 / 6
measures where SGHT leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | RVMD · FY2025 | SGHT · FY2025 |
|---|---|---|
| Revenue | $0 | $77.4M |
| Net income | (1.1B) | (38.4M) |
| Revenue growth (yearly, multi-year) | -37.2% | 12.1% |
| Free cash flow | (913.7M) | (29.9M) |
| Free cash flow margin | — | -38.7% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -58.1% | -50.7% |
| Gross margin | — | 86.2% |
| Operating margin | — | -48.0% |
| Net debt / EBITDA | 0.33x | 1.41x |
Figures are as reported by each company; latest fiscal year shown.
Where Revolution Medicines, Inc.'s cash went (FY2025)
- Capital spending
- $16.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Sight Sciences, Inc.'s cash went (FY2025)
- Capital spending
- $224000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free